Roche: Ocrevus Zunovo approved by FDA

(CercleFinance.com) - Roche announces that the US FDA has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS).


This is the first and only subcutaneous injection of around 10 minutes administered by a healthcare professional twice a year and approved for these two forms of multiple sclerosis, giving patients more treatment options.

This approval is based on the Phase III OCARINA II trial, which showed no clinically significant difference in Ocrevus blood levels when administered subcutaneously, compared with the intravenous formulation.


Copyright (c) 2024 CercleFinance.com. All rights reserved.